EP1221961A1 - Induction of a strong immune response to a self-tumor associated antigen - Google Patents
Induction of a strong immune response to a self-tumor associated antigenInfo
- Publication number
- EP1221961A1 EP1221961A1 EP00970926A EP00970926A EP1221961A1 EP 1221961 A1 EP1221961 A1 EP 1221961A1 EP 00970926 A EP00970926 A EP 00970926A EP 00970926 A EP00970926 A EP 00970926A EP 1221961 A1 EP1221961 A1 EP 1221961A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antigen
- self
- maa
- hmw
- tumor associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 183
- 108091007433 antigens Proteins 0.000 title claims abstract description 154
- 102000036639 antigens Human genes 0.000 title claims abstract description 154
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 56
- 230000028993 immune response Effects 0.000 title claims abstract description 34
- 230000006698 induction Effects 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 67
- 230000003278 mimic effect Effects 0.000 claims abstract description 36
- 230000003053 immunization Effects 0.000 claims abstract description 35
- 238000002649 immunization Methods 0.000 claims abstract description 32
- 230000001965 increasing effect Effects 0.000 claims abstract description 10
- 230000004044 response Effects 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 81
- 201000001441 melanoma Diseases 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 208000035475 disorder Diseases 0.000 abstract description 4
- 102000004127 Cytokines Human genes 0.000 abstract description 3
- 108090000695 Cytokines Proteins 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 abstract description 2
- 108020003175 receptors Proteins 0.000 abstract description 2
- 102000005962 receptors Human genes 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 abstract 1
- 102000006240 membrane receptors Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 48
- 108020004414 DNA Proteins 0.000 description 33
- 210000003719 b-lymphocyte Anatomy 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000000890 antigenic effect Effects 0.000 description 10
- 230000009257 reactivity Effects 0.000 description 10
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 8
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 108010067902 Peptide Library Proteins 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 238000002823 phage display Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- 238000011830 transgenic mouse model Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 210000004201 immune sera Anatomy 0.000 description 6
- 229940042743 immune sera Drugs 0.000 description 6
- 238000004091 panning Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 101000608782 Mus musculus Tyrosinase Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229920006355 Tefzel Polymers 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical compound C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Definitions
- the present invention relates to a method for enhancing the efficacy of an immune response against an antigen which is a self-antigen.
- the method of the invention comprises (i) immunization of a host with a mimic of the self-antigen to break tolerance to a self antigen, and (ii) increasing the response to the self-antigen by a booster with the original antigen.
- An immune response may be generated against any self antigen including, for example, tumor associated antigens, cell surface receptors, receptor Hgands, cytokines, hormones, or a self antigen whose expression is associated with a disease or disorder.
- the method of the invention may be used to target destruction of targeted tumor cells bearing tumor associated antigens in cancer subjects through induction of an immune response.
- immunogens which have been shown to be effective in inducing an immune response to a self-antigen include peptide mimics (WO 00/38515; US Patent No. 5,679,647) including, for example, xenogenic tumor associated antigens which display a high degree of homology, but not complete identity in their amino acid sequence with a self-antigen (Naftzger et al., 1996, Proc. Natl. Acad. Sci. USA., 93:14809-14814; Overwijk et al., 1998, J.
- Anti-id antibodies which mimic various types of tumor associated antigens have been used as immunogens in clinical trials (for review, see Shoenfeld et al, supra). In at least three antigenic systems, anti-id antibodies have been found to be more effective than the corresponding antigen in breaking tolerance to a self-antigen, since they have elicited antigen binding antibodies, while the corresponding nominal antigen has not (Von Kleist et al., 1966, Immunology, 10:507-515; Collatz et al., 1971, Int. J. Cancer, 8:298-303; Lo Gerfo et al., 1972, Int. J.
- the lack of immunogenicity of a self antigen is likely to reflect the deletion during the establishment of self-identity, of B cell clones that recognize the antigen with high affinity.
- the immunogenicity of the corresponding anti- id antibody is likely to reflect its ability to stimulate B cell clones which have not been deleted during the establishment of self-identity, since they secrete antibodies reacting with the corresponding antigen with an affinity below the threshold required for deletion.
- Anti-id antibodies which are similar, but not identical to the nominal antigen stimulate B cell clones secreting antibodies which fit poorly antigenic determinants expressed on the self-antigen.
- the present invention relates to a method for stimulating an immune response against an antigen which is a self-antigen.
- the method of the invention comprises (i) immunization of a host with a mimic of the self-antigen to break tolerance to the self antigen, and (ii) increasing the response to the self-antigen by a booster with the original antigen.
- the method may be used to generate an immune response against any self antigen.
- the self antigen comprises a tumor associated antigen
- the present invention provides a method for increasing the efficacy of active specific immunotherapy for malignant diseases.
- FIG. 1 SDS-PAGE analysis of antigens immunoprecipitated from 125 I-labeled Colo 38 melanoma cells by sera from a rabbit sequentially immunized with the anti-id mAb MK2-23 and with melanoma cells Colo 38.
- Rabbits 97-6 was immunized on day 0, 14, 28 and 42 with KLH conjugated mouse anti-id mAb MK2- 23 mixed with Freund's adjuvant and on day 63 with cultured human melanoma cells Colo 38 (1 x 10 6 ).
- the present invention relates to a method for enhancing the efficacy of an immune response against an antigen which is a self-antigen.
- the method of the invention comprises (i) immunization of a host with a mimic of the self-antigen to break tolerance to the self antigen, and (ii) increasing the response to the self-antigen by a booster with the original antigen.
- the method may be used to generate an immune response against any self antigen.
- a novel immunization strategy is provided to elicit a strong immune response to a tumor associated antigen which is a self-antigen.
- the method comprises immunization of hosts with antigens which are similar, but not identical to the original tumor associated antigens.
- the steps of the invention involve (i) first immunizing a host with a mimic of the tumor associated antigen to break unresponsiveness to a self-antigen, and (ii) increasing the response to the self-antigen by a booster with the original antigen.
- HMW-MAA human high molecular weight-melanoma associated antigen
- the present invention provides active immunotherapy of disorders, such as cancer, by utilizing as immunogens mimics of self-antigens.
- the method comprises immunization of hosts with a mimic comprising an antigen which is similar, but not identical to the original self antigen.
- mimics are defined as those peptides capable of eliciting immunity to a self antigen.
- Peptide mimics of self antigens may be identified by screening peptide libraries.
- phage display peptide libraries may be panned with, for example, human or mouse antibodies immunoreactive with the targeted self antigen.
- mimics may comprise analogous self-antigens derived from other species, peptides similar to self antigens but having amino acid alterations, or denatured self antigens, for example. Certain aspects of the invention are described below for tumor associated antigens, however, the principles of the invention may be applied to any self antigen.
- Mimics of self antigens that can be used to break tolerance to a self- antigen include, but are not limited to, (i) peptide mimics of the self antigen; (ii) a nucleic acid molecule capable of encoding such a peptide mimic; (iii) or anti-idiotypic antibodies of a self antigen which bear the internal image of said self antigen. Nucleic acid molecules capable of encoding peptide mimics can be RNA or DNA or derivatives or modified versions thereof, single-stranded or double-stranded.
- Mimics of a tumor associated antigen may relate to a fragment of an antigen, epitope, or antigenic determinant.
- the self-antigen is a tumor associated antigen.
- Peptide mimics of self antigens may be identified by panning phage display peptide libraries with, for example, human or mouse antibodies immunoreactive with the targeted self antigen. Such phage libraries are commercially available (Pharmacia), or alternatively, phage libraries may be constructed using routine techniques known in the art. Peptide mimics may include B cell defined epitopes of a tumor associated antigens identified through panning a phage display library with human and/or mouse anti-tumor associated antigen antibodies. Once a phage expressing a peptide mimic has been identified the DNA sequence and deduced amino acid sequence of the peptide mimic may be determined. Such information may then be advantageously used to produce peptide mimics for use as immunogens. Additionally, peptide mimics that can be used to break tolerance include, but are not limited to, those described in WO OO/38515 incorporated by reference herein.
- Identified peptide mimics may be chemically synthesized using routine techniques known in the art.(e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y.).
- the peptide mimics may be modified to enhance their ability to stimulate an immune response in the immunized host.
- the peptide mimic may be modified by conjugation to an immunogenic reagent, such as a polysaccharide or peptidoglycan, or by glycosylation of the peptide mimic.
- the peptide mimics may be modified by haptenization of the peptide mimic.
- nucleic acid molecules capable of encoding peptide mimics may also be prepared for use as immunogens by any method known in the art for the synthesis of DNA and RNA molecules.
- the nucleic acids may be chemically synthesized using commercially available reagents and synthesizers by methods that are well known in the art (see, e.e., Gait, 1985, Oligonucleotide Synthesis: A Practical Approach, IRL Press, Oxford, England).
- the nucleic acids may be purified by any suitable means, as are well known in the art.
- the peptide mimics may be advantageously produced by recombinant DNA technology using techniques well known in the art for expressing a nucleic acid containing gene sequences and/or coding sequences for peptide mimics. Such methods can be used to construct expression vectors containing nucleotide sequences encoding peptide mimics and appropriate transcriptional and translational control signals. Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; and Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY.
- the nucleic acid encoding the peptide mimic of interest may be recombinantly engineered into a variety of host vector systems that also provide for replication of the nucleic acid in large scale and contain the necessary elements for directing the transcription of the nucleic acid.
- the use of such a construct to immunize a subject will result in the transcription of sufficient amounts of RNA encoding the peptide mimic thereby facilitating the induction of an immune response directed against the peptide mimic.
- a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of the nucleic acid molecule encoding the peptide mimic.
- Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired peptide, i.e., the peptide mimic.
- Such vectors can be constructed by recombinant DNA technology methods standard in the art.
- Vectors encoding the peptide mimic of interest can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the peptide mimic can be regulated by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive.
- Such promoters include but are not limited to: the SV40 early promoter region (Benoist, C. and Chambon, P.
- any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site.
- viral vectors can be used which selectively infect the desired target cell.
- a DNA minigene encoding a peptide mimic may be genetically engineered and used as an immunogen to break host tolerance to a self antigen.
- peptide mimics include but are not limited to peptide mimics of tumor associated antigens and/or peptide mimics of B cell epitopes of tumor associated antigens.
- the minigene for use in breaking tolerance to a self antigen comprises (i) nucleic acid molecules encoding peptide mimics, including for example, peptide mimics of B cell determinants of a targeted self antigen; (ii) a universal helper epitope, such as PADRE, which elicits helper function for differentiation of antigen specific B cells into plasma cells; and (iii) a signal peptide that directs secretion of the expressed protein into the extra cellular space thereby facilitating antigen uptake by antigen specific cells.
- the order of the sequences in the minigene will consist of signal sequence, sequence of the helper peptide PADRE followed by sequences encoding the peptide mimics of B cell determinants of HMW-MAA.
- the 5' end oligonucleotide sequences of the minigene will contain sequences encoding the restriction enzyme site Nhel and the Kozak consensus sequence to facilitate translation of the mRNA.
- the 3' end oligonucleotide of the minigene will contain an in frame termination codon and a restriction enzyme site Kpnl. The different restriction enzyme sites at the 5' and 3' ends of the minigene will allow its directional cloning into various expression vectors, such as those described above.
- anti-idiotypic antibodies may be utilized as mimics of self antigens.
- anti-idiotypic antibodies and fragments thereof, the antigen binding sites of which immuno-specifically bind to antibodies that recognize a self antigen, such as a tumor associated antigen may be used to immunize a host.
- Methods for generating such anti-idiotypic antibodies are well known to those skilled in the art (Kennedy et al., 1983, Science 221 :853-854; Kennedy et al., 1986, Science 232:220-223; Kieber-Emmons, TRE et al., 1986, Int. Rev.
- Immunol. 1 :1-26) an antibody reactive with a self antigen, or hybridomas producing such antibodies, can be used as an immunogen. Immunizations are accomplished using standard procedures. The unit dose and immunization regimen will depend on the species of mammal immunized. Typically, the immunized mammals are bled and the serum from the blood sample is assayed for the presence of anti-idiotypic antibodies. Anti-idiotypic polyclonal antibodies may be directly purified from the serum of the immunized animal. Alternatively, technology for producing monoclonal antibodies may be utilized to generate hybridoma cell lines that produce anti-idiotypic antibodies. The conditioned hybridoma culture supernatant may be collected and the antibodies purified by conventional methods.
- the present invention relates to a method for enhancing the efficacy of an immune response against a self antigen, such as a tumor associated antigen.
- the method of the invention comprises two steps, first, immunization of a host with a mimic of the self antigen to break tolerance, and second, increasing the response to self-antigen by a booster with the original antigen.
- Mimics of tumor associated antigens that may be used to break tolerance in hosts suffering from diseases characterized by the production of the tumor associated antigens include, for example, peptide mimics, nucleic acid molecules capable of expressing such peptide mimics, and/or anti-idiotypic antibodies. Stimulation of an immunological response to such antigens, is intended to elicit a more effective attack on tumor cells; such as inter alia inhibiting tumor cell growth or facilitating the killing of tumor cells.
- mimics of self antigens may be used to break tolerance in hosts suffering from disorders or diseases associated with expression of specific self antigens. Stimulation of an immunological response to such antigens is intended to remove the self antigen from the host's system, or alternatively, for targeted destruction of cells expressing such self antigens.
- the mimics for use as immunogens can be prepared using the methods described in Section 5.1.
- the mimic to be used for immunization comprises a nucleic acid molecule formulation
- various delivery systems are known and can be used to transfer the formulations of the invention into cells, e.g. encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mimic, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a nucleic acid as part of a retroviral or other vector, injection of DNA, electroporation, calcium phosphate mediated transfection, etc.
- the mimics may be formulated with a suitable adjuvant in order to enhance the immunological response to the antigen.
- suitable adjuvants include, but are not limited to mineral gels, e.g. aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, and potentially useful human adjuvants such as BCG (Bacilli Calmett- Gueri ⁇ ) and (Corynebacterium parvum).
- compositions derived above including but not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous.
- the methods and compositions for the introduction of an antigenic composition into an individual are well known to those skilled in the art.
- the mimics will be administered in amounts which are effective to produce the desired effect, i.e., the induction of an immune response to self antigens, such as tumor associated antigens, in the immunized host.
- Effective doses of the mimics can be determined through procedures well known in the art.
- a variety of different methods may be utilized to determine whether an immune response to a self antigen has been stimulated in the immunized host. Such methods include western blots, immunoprecipitation followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunocytochemistry, etc..
- the initial priming with the peptide mimics of self antigens will induce low titer, low avidity anti- mimic antibodies in the immunized host, since the encoded determinants are similar, but not identical to those of the self-antigen.
- This characteristic of the immunization which underlies its ability to break unresponsiveness to antigens, results in the stimulation of B clones secreting antibodies with low avidity for self antigens.
- B clones secreting antibodies with low avidity for self antigens.
- clones secreting the mutated antibodies may be expanded by booster(s) with the original self antigen.
- the antigens that may be used to enhance the immune response include tumor cells expressing the tumor associated antigen, purified tumor associated antigen, peptides derived from the sequence of the tumor associated antigen and nucleic acid molecules, such as minigene constructs, capable of expressing the tumor associated antigen.
- the level of anti-tumor associated antigen antibodies is monitored in the host's serum.
- EXAMPLE ENHANCEMENT BY A BOOSTER WITH HMW-MAA BEARING CULTURED HUMAN MELANOMA CELLS
- Rabbits 97-6 and 97-7 were immunized on day 0, 14, 28 and 42 with the mouse anti-id mAb MK-23 conjugated to KLH (300 ⁇ g/injection) and mixed with Freund's adjuvant. Rabbits express the HMW-MAA with a tissue distribution and an antigenic profile similar to those of the human counterpart (Schlingemann, R.O, et al., 1990, Am. J. Pathol. 136:1393-1405).
- the anti-id mAb MK2-23 bears the internal image of HMW-MAA (Mittelman, A. et al., 1992, Proc. Natl. Acad. Sci. USA 89:466-470; Kasuama M., et al., 1989, J. Immunol, 143:3844-3852; Chen, Z.J. et al., 1993, Cancer Res. , 53:1 12- 119).
- Sera harvest on day 49 displayed a low reactivity with HMW-MAA bearing melanoma cells Colo 38 (Fig. 1), but did not immunoprecipitate HMW-MAA from radiolabelled melanoma cells (Fig. 2). Rabbits were boosted with Colo 38 cells on day 56.
- the human scFv C21 and the mouse mAb 149.53, 225.28, 763.79, GH704 and TP61.5 recognize distinct antigenic determinants of HMW-MAA.
- Panning phage display peptide libraries LX-8 and XI 5 (Morgan, D.J. et al., 1998, J. Immunol, 160:643-651) with HMW-MAA binding human scFv C21 and mouse mAb 149.53, 225.28, 763.79, GH704 and TP61.5 following the methodology described by Bonnycastle et al. (Bonnycastle, L.L. et al., 1996, J. Mol.
- a DNA minigene encoding peptide mimics of B cell epitopes of human HMW-MAA is tested for its ability to trigger the immune response to HMW- MAA in hosts with a constitutive expression of this antigen.
- the minigene has been selected as the immunogen to break tolerance to HMW-MAA, since minigenes have been shown to be highly immunogenic.
- mice transgenic for human HMW-MAA and rabbits include mice transgenic for human HMW-MAA and rabbits.
- Mice transgenic for human HMW-MAA will be utilized because they are suitable for testing a large number of variables which may influence the immunogenicity of DNA minigene; they provide a source of hosts with a defined and standardized genetic background which minimizes the variability in the host's immune response; and they allow the testing of variables, i.e. cytokines, dendritic cells, which cannot be tested in other animal species due to the unavailability of reagents and/or methodology.
- Rabbits are also used in the experiments, since they express the HMW- MAA with a tissue distribution and an antigenic profile similar to those observed in humans. Rabbits are tested to determine the effect of similarity, but not identity between rabbit and human HMW-MAA on the host's immune response using the methods described herein.
- the minigene used in this study consists of (i) oligonucleotide sequences encoding peptide mimics of B cell determinants of HMW-MAA, (ii) a universal helper epitope PADRE that elicits help for differentiation of antigen specific B cells into plasma cells, and (iii) a signal peptide.
- the signal peptide will direct secretion of the expressed protein into the extracellular space facilitating antigen uptake by antigen specific B cells.
- the minigene is constructed following published procedures ( Ishioka, G.Y. et al., 1999, J. Immunol, 162:3915-3925).
- the order of sequences in the minigene consist of signal sequence, sequence of the helper peptide PADRE followed by sequences encoding the peptide mimics of B cell determinants of HMW-MAA.
- there are no intervening sequences between neighboring peptide sequences so that all peptide sequences are part of a single open reading frame.
- the 5' end oligonucleotide sequences of the minigene contains sequences encoding the restriction enzyme site Nhel and the Kozak consensus sequences to facilitate translation of the mRNA.
- the 3' end oligonucleotide of the minigene will contain an in frame termination codon and a restriction enzyme site Kpnl.
- the different restriction enzyme sites at the 5' and 3' ends of the minigene will permit directional cloning into the pcDNA3.1 expression vector.
- the total length of the minigene is 255 nucleotides. This includes a 120-nucleotide long 5' region containing the 5' Nhel restriction site, the Kozak sequence, the signal peptide and the PADRE sequence.
- the 3' part of the minigene is 135 nucleotides long and contains sequences encoding the three peptide mimics, the termination codon and the 3' end Kpnl restriction site. These two parts are assembled separately.
- the 5' part is assembled as a 135 nucleotide long cDNA since it also includes a 15 overlap with the 3' part.
- Two overlapping oligonucleotide primers including a 75 mer sense primer and a 75 mer antisense primer with a central overlapping segment of 15 nucleotides is annealed and extended in a PCR to yield a 135 nucleotide long cDNA product.
- the cDNA is purified by electrophoresis on an agarose gel.
- the 3' part is similarly assembled separately. It is assembled as a 135 nucleotide long cDNA since the central overlap segment between the 5' and 3' parts is provided by the 5' part.
- the 3' part of the minigene is assembled with two overlapping oligonucleotide primers including a 75 mer sense primer and a 75 mer antisense primer with a 15 nucleotide overlap at their 3' ends.
- the two primers are annealed and extended in a PCR for 10 cycles and the resulting 135 nucleotide long cDNA purified by electrophoresis on an agarose gel.
- the gel purified 5' and 3' parts of the minigene are mixed together and carried through 10 cycles of PCR to yield a 255 nucleotides long minigene.
- This full-length minigene is selectively amplified using two 25 mer primers from the 5' and 3' ends of the minigene.
- the cycling conditions of the PCR amplifications are 95°C, 15 sec. for denaturation; 5°C below the calculate melting temperature of the overlapping segments of the oligonucleotide for 30 sec. for annealing and 72°C for 1 min. for DNA synthesis.
- the 255 nucleotide long minigene is then purified by agarose gel electrophoresis and cloned in the vector pCR2.1 (Invitrogen). Individual clones are isolated and sequenced to confirm their sequence identity.
- the minigene is excised from the pCR2.1 vector by digestion with Nhel and Kpnl enzymes and re-cloned into the same restriction sites of the expression vector pcDNA 3.1.
- a cDNA library is constructed from two micrograms of poly(A)+ RNA isolated from A385 met human melanoma cells.
- An oligo(dT)primer adapter containing a Notl site is used for priming first-strand cDNA with Superscript II RNase H- reverse transcriptase (Gibco BRL).
- Double-stranded cDNAs is generated using the rest of the Superscript cDNA synthesis system followed by a Sal I adapter ligation and Not I digestion. All of the recovered double-stranded cDNAs are ligated into Not I/Sal I sites of a lambda vector.
- the ligated cDNA/phage DNA mixtures are packaged using Gigapack Gold packaging extracts (Stratagene) and titered according to the manufacturer's specifications.
- the above cDNA library members are screened using 32 P labeled PCR product as a probe at 1 x 10 6 cpm/ml of hybridization solution (50% formamide/5X Denhardt's solution/1 % SDS/6X SSPE/0.2 mg/ml salmon sperm DNA) at 42°C for 16 hrs.
- Membranes will be rinsed in IX SSC/0.5% SDS at room temperature for 30 min. and then in O.1X SSC/0.5% SDS at 65°C for 30 min. prior to autoradiography.
- Isolated clones with expected sizes are sequenced in their entirety at least two times per nucleotide using the Prism Ready Reaction Cycle Sequencing system (Perkin Elmer).
- the synthetic oligonucleotide shown in Table II are designed according to the sequence of chosen unique restriction sites for convenient cloning.
- the recognition sites for restriction enzymes are underlined.
- MICE TRANSGENIC FOR HUMAN HMW-MAA After removal of vector sequences by cleavage with BssHII, the minigene is isolated from a low-gelling temperature agarose gel and purified with glass powder (Geneclean; Bio 101) followed by dialysis against injection buffer (10 mM Tris.HCL, pH 7.5/0.1 mM EDTA) on dialysis filters (Millipore).
- Approximately 500-1,000 copies (1-2 pi of 2-5 ng/ ⁇ l DNA soln.) of the transgene is injected into the male pronucleus which allows easier introduction of the injection needle as it is larger in size than female's.
- Approximately 200 eggs are injected during each day of microinjection. After microinjection, eggs are cultured in 5% C02 incubator, and in the following day, transferred into the oviduct of pseudopregnant female at the 2-cell stage. Offspring are usually born 19 days after the transfer.
- Transgene integration is screened initially by polymerase chain reaction (PCR) analysis and subsequently confirmed by Southern analysis of tail
- transgenic animals DNA purified from each offspring. Only transgene positive animals are backcrossed to original strain of mice to establish transgenic mouse strains. As founder transgenic animals (GO: generation 0) may be chimeric in copy number and integration site of the transgene in germ cells, the next generation of animals (Gl) are thoroughly investigated for transgene segregation. After establishment of transgenic mouse lines a subset of the mice are sacrificed and tested for RNA and protein expression in various tissue utilizing Northern blot and immunohistochemistry. One or two representative transgenic lines in which the transgene is highly expressed are selected for further experimentation. It is expected that expression of the HMW-MAA genes is induced in melanocytes. All techniques described here are routine. (Reilly, M.P. et al., 1994, Academic Press, New York, pp. 403-434; Katsumata, M. et al., 1995 Nature Medicine, 1 :644-648).
- the C57BL6/J inbred strain is chosen to produce transgenic animals since its genetic and physiological background are well characterized, although, the use of inbred mice is sometimes not suitable for obtaining sufficient numbers of properly fertilized eggs, and highly viable embryos for microinjection. In addition to this, reproduction of inbred mice is relatively poor. This low reproductivity is mostly due to insufficient mating ability of male mice. To overcome this problem several (Waldman, T.A., 1991, Science, 252:1657-1662; von-Mehren, et al., 1996, Curr. Opin. Oncol, 8:493-498) male mice are raised in the same cage to induce competition among the animals so that only one dominant male can mate.
- T-cell receptor gene transgenic mice have been efficiently produced using this approach. To obtain sufficient numbers of fertilized eggs, larger numbers (up to fifteen) of females are used for the mating. Each female produces at least 10-20 properly fertilized eggs although the proportion of unhealthy eggs is high. If in vitro survival of those embryos appears poor, the embryos will be transferred the same day of microinjection.
- DNA coated particles are then pelleted at 12,000 for 30 sec, washed three times with 100% ethanol and resuspended in 3 ml of ethanol.
- a 21 inch long Tefzel tubing (l/8th inch outside diameter, 3/32 inch internal diameter) is filled with the suspension and laid flat for 10 min. to allow the particles to settle.
- the ethanol is then decanted, and the tubing is manually rotated to coat the inner walls with the particles.
- the tubing is then dried in a stream of nitrogen gas for 3-5 min. Individual shots are generated by cutting the tubing into Vi inch length, each containing 1 ⁇ g/0.5 mg gold and loaded into 12-shot barrels of a helium-driven gene gun.
- mice are anesthetized with ketamine (30 mg/kg) and xylazine (3mg/kg). Hair is clipped from a 100 cm 2 area on mice backs, and residual hair and superficial keratin are treated with a commercial depilatory.
- the gene gun is held against the skin and each shot is inoculated by instantaneous release of 350 psi of helium pressure through the barrel.
- mice are inoculated at 10 sites. The primary immunization is given on day 0, and booster immunizations on days 21 and 42. Sera are obtained prior to primary immunization and 10 days after each booster immunization.
- mice Ten rabbits are immunized with the DNA minigene encoding peptide mimics of B cell epitopes of HMW-MAA utilizing the methodology described for mice. The detection and characterization of anti-HMW-MAA antibodies will be performed as described above. Rabbits (10/group) immunized with a DNA minigene encoding peptide mimics of B cell determinants of HMW-MAA are boosted with a DNA minigene encoding a fragment of HMW-MAA expressing the corresponding native B cell determinants, utilizing the methodology described above.
- the binding of antibodies is detected using biotinylated anti-mice IgG and anti-mice IgM xenoantibodies.
- the specificity of the binding is assessed by testing immune sera for binding to lymphoid cells, which do not express HMW-MAA and by testing melanoma cells with preimmune sera and sera from mice immunized with a minigene encoding an unrelated peptide.
- the specificity of immune sera for HMW-MAA is assessed by SDS- PAGE analysis of components immunoprecipitated from 125 I- or 35 S-labelled melanoma cells and by sequential immunoprecipitation utilizing anti-HMW-MAA rnAb as a reference. Radio-labeling of cells, solubilization of cells, immunoprecipitation, SDS-PAGE and autoradiography or fluorography is performed utilizing procedures that have been extensively utilized (Chen, Z.J. et al., 1993, Cancer Res., 53:112-119).
- HMW-MAA HMW-MAA purified from a melanoma cell extract by binding to a microtiter plate coated with an anti-HMW- MAA mAb.
- the latter recognizes a determinant distinct and spatially distant from those encoded by DNA minigene.
- the binding of antibodies to HMW-MAA is detected with biotinylated anti -mouse IgG Fc xenoantibodies. The specificity of the binding is monitored utilizing plates coated with an unrelated antigen.
- Sera containing HMW-MAA binding antibodies is tested for staining of melanoma lesions in the immunoperoxidase reaction (Schlingemann, R.O., et al., 1990 Am. J. Pathol, 136:1393-1405), to prove that the antibodies react with the antigen in vivo. If the results are not reliable because of high background, antibodies will be purified by affinity chromatography on synthetic peptides and used to stain melanoma lesions and control tissues in the immunoperoxidase reaction.
- Cross blocking experiments is used to map the antigenic determinant recognized by antibodies present in immune sera.
- melanoma cells are incubated with saturating amounts (20 ⁇ g/well) of F(ab') 2 fragments of mouse monoclonal antibodies or of human scFv fragments recognizing the determinants encoded by the DNA minigene.
- immune sera are added to cells and the binding of antibodies is detected using biotinylated anti-mouse IgG Fc xenoantibodies.
- Immune sera is tested for its ability to inhibit the binding to melanoma cells of monoclonal antibodies and scFv fragments recognizing determinants encoded by the DNA minigene.
- melanoma cells are coated with immune sera and then tested for their ability to biotynilated monoclonal antibodies and seFv fragments recognizing the determinants encoded by the DNA minigene.
- the specificity of these assays is assessed using mAb and antisera recognizing unrelated antigens.
- mice (10/group) immunized with a DNA minigene encoding peptide mimics of ⁇ cell determinants of HMW-MAA are boosted with a DNA minigene encoding a fragment of HMW-MAA expressing the corresponding native B cell determinants.
- mice are immunized at biweekly intervals with four injections of the DNA minigene encoding peptide mimics of B cell determinants of HMW-MAA and one with a DNA minigene encoding a fragment of HMW-MAA expressing the corresponding native B cell determinants.
- Controls include immunizations with an unrelated DNA minigene.
- the level of anti-HMW-MAA antibodies is monitored in sequential bleedings from mice following the methodology described above.
- the increase in the reactivity with melanoma cells of sera from mice following a booster encoding a fragment of HMW-MAA may reflect an increase of the antibody population elicited by the minigene encoding peptide mimics of HMW-MAA or determinant spreading (Secarz, E., 1998, Immunol. Rev., 164:5-264).
- sera from rabbits is tested for their susceptibility to inhibition in their binding to melanoma cells by the mAb used to identify the peptide.
- the specificity of the inhibition is assessed using unrelated mAb and antisera.
- HLA-A2 A*0201
- HLA-A2/Kb transgenic mice are used to identify immunogenic HLA-A2 restricted, T cell epitopes of HMW- MAA, because their CTL reptoire has been shown to be similar, if not identical, to that in humans (Wentworth PA, 1996, Eur. J. Immunol. 26:67-101).
- HMW-MAA DNA minigene to induce HLA-A2 restricted, HMW-MAA specific CTL will be tested utilizing mice transgenic for human HMW-MAA and for HL A-A2 antigen. The latter are generated by crossing HLA-A2 transgenic mice with HMW- MAA transgenic mice.
- HMA-MAA specific CTL epitopes defined in the animal model will be tested for their ability to generate in vitro HLA-A2 -restricted, HMW- MAA specific CTL utilizing PBMC from patients with malignant melanoma. Two approaches will be used for identification of HLA Class I antigen restricted CTL epitopes.
- CTL are induced by immunization with peptides derived from the sequence of target antigen, expanded by in vitor stimulation with antigen presenting cells (APC) pulsed with the immunizing peptides followed by evaluation for their capability to recognize target cells expressing the antigen.
- APC antigen presenting cells
- CTL are generated by immunization with cDNA followed by in vitro stimulation with cDNA transfected APC and then testing on target cells pulsed with peptides.
- cDNAs are likely to be better immunogens than peptides when engineered like minigenes to contain sequences encoding an helper epitope and the signal peptide.
- the peptides to be used in both approaches are selected on the basis of HLA- A2 binding motifs identified with a computer program (Parker et al., 1994, J. Immunol. 152:163-175).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15915399P | 1999-10-13 | 1999-10-13 | |
US159153P | 1999-10-13 | ||
PCT/US2000/028517 WO2001026672A1 (en) | 1999-10-13 | 2000-10-13 | Induction of a strong immune response to a self-tumor associated antigen |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1221961A1 true EP1221961A1 (en) | 2002-07-17 |
EP1221961A4 EP1221961A4 (en) | 2004-03-31 |
Family
ID=22571310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00970926A Withdrawn EP1221961A4 (en) | 1999-10-13 | 2000-10-13 | Induction of a strong immune response to a self-tumor associated antigen |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1221961A4 (en) |
JP (1) | JP2003514774A (en) |
AU (1) | AU8024100A (en) |
CA (1) | CA2385186A1 (en) |
WO (1) | WO2001026672A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE50111493D1 (en) * | 2001-09-03 | 2007-01-04 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Antigen mimotope and vaccine against cancer |
RU2422460C2 (en) | 2003-12-31 | 2011-06-27 | Шеринг-Плоу Лтд. | Recovered peptide exhibiting specific anti-gdf-8 antibody binding activity, recovered nucleic acid molecule, expression vector, host cell, method for producing peptide, vaccine composition and method of eliciting anti-gdf-8 immune response, method of anti-gdf-8 antibody selection screening and method of gdf-8 activity down-regulation in animal |
TW200634156A (en) * | 2004-12-30 | 2006-10-01 | Schering Plough Ltd | Neutralizing epitope-based growth enhancing vaccine |
US8318162B2 (en) | 2009-07-16 | 2012-11-27 | Xoma Technology Ltd. | Antibodies to high molecular weight melanoma associated antigen |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0759442A1 (en) * | 1987-09-10 | 1997-02-26 | Oncogen Limited Partnership | Tumor immunotherapy using anti-idiotypic antibodies |
WO1997023237A1 (en) * | 1995-12-22 | 1997-07-03 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
US5780029A (en) * | 1989-11-14 | 1998-07-14 | New York Medical College | Antidiotypic monoclonal antibodies for treatment of melanoma |
WO2000038515A1 (en) * | 1998-12-24 | 2000-07-06 | New York Medical College | Peptide mimics useful for treating disease |
-
2000
- 2000-10-13 AU AU80241/00A patent/AU8024100A/en not_active Abandoned
- 2000-10-13 CA CA002385186A patent/CA2385186A1/en not_active Abandoned
- 2000-10-13 WO PCT/US2000/028517 patent/WO2001026672A1/en active Application Filing
- 2000-10-13 EP EP00970926A patent/EP1221961A4/en not_active Withdrawn
- 2000-10-13 JP JP2001529734A patent/JP2003514774A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0759442A1 (en) * | 1987-09-10 | 1997-02-26 | Oncogen Limited Partnership | Tumor immunotherapy using anti-idiotypic antibodies |
US5780029A (en) * | 1989-11-14 | 1998-07-14 | New York Medical College | Antidiotypic monoclonal antibodies for treatment of melanoma |
WO1997023237A1 (en) * | 1995-12-22 | 1997-07-03 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
WO2000038515A1 (en) * | 1998-12-24 | 2000-07-06 | New York Medical College | Peptide mimics useful for treating disease |
Non-Patent Citations (7)
Title |
---|
DURRANT L G ET AL: "Development of second generation monoclonal antibodies recognising Lewis-y!b antigen by anti-idiotypic immunisation" HYBRIDOMA, vol. 12, no. 6, 1993, pages 647-660, XP008005496 ISSN: 0272-457X * |
DYALL R ET AL: "HETEROCLITIC IMMUNIZATION INDUCES TUMOR IMMUNITY" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 188, no. 9, 2 November 1998 (1998-11-02), pages 1553-1561, XP002947142 ISSN: 0022-1007 * |
FERRONE SOLDANO: "Active specific immunotherapy of human melanoma with mouse anti-idiotypic (anti-id) monoclonal antibodies (MAB)" MEDICAL INTELLIGENCE UNIT;IMMUNOTHERAPY OF MALIGNANT MELANOMA, 1996, pages 73-95, XP009024959 Chapman and Hall, Inc., 29 West 35th Street, New York, New York, USA; Chapman and Hall Ltd., 2-6 Boundary Row, London SE1 8HN, England ISBN: 0-412-10491-1 * |
PARKHURST M R ET AL: "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 SEP 1996, vol. 157, no. 6, 15 September 1996 (1996-09-15), pages 2539-2548, XP002096010 ISSN: 0022-1767 * |
ROSENBERG S A ET AL: "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma" NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 3, 1 March 1998 (1998-03-01), pages 321-327, XP002091661 ISSN: 1078-8956 * |
See also references of WO0126672A1 * |
WANG X ET AL: "IMMUNOTHERAPY OF MELANOMA: PEPTIDE MIMICS OF A HUMAN HIGH MOLECULARWEIGHT-MELANOMA ASSOCIATED ANTIGEN" MEDICINA, BUENOS AIRES, AR, vol. 60, no. SUPPL 2, August 2000 (2000-08), pages 48-50, XP001053496 ISSN: 0025-7680 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001026672A1 (en) | 2001-04-19 |
CA2385186A1 (en) | 2001-04-19 |
WO2001026672A9 (en) | 2002-08-01 |
AU8024100A (en) | 2001-04-23 |
EP1221961A4 (en) | 2004-03-31 |
JP2003514774A (en) | 2003-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4658423B2 (en) | Polypeptides and polynucleotides for enhancing immunoreactivity against HER-2 protein | |
US7090842B1 (en) | Murine monoclonal anti-idiotype antibody 3H1 sequences for human carcinoembryonic antigen | |
Amici et al. | Genetic immunization against neu/erbB2 transgenic breast cancer | |
JP2011098980A (en) | Anti-neovasculature preparation for cancer | |
US7083943B1 (en) | Polynucleotides related to murine anti-idiotype antibody 11D10 and methods of use thereof | |
SK4272001A3 (en) | Methods for therapeutic vaccination | |
US8187600B2 (en) | Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses | |
JPH11502405A (en) | p15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods | |
JP2007523610A (en) | Synthetic genes encoding carcinoembryonic antigen and uses thereof | |
EP1221961A1 (en) | Induction of a strong immune response to a self-tumor associated antigen | |
WO1999045018A1 (en) | Active immunization against angiogenesis-associated antigens | |
JP2003517845A (en) | Improved nucleic acid vaccination | |
JP3683278B2 (en) | Mouse monoclonal anti-idiotype antibody 11D10 and method of use thereof | |
JP2002533357A (en) | Peptide mimics useful for treating diseases | |
Veelken et al. | Vaccination strategies in the treatment of lymphomas | |
ZA200102603B (en) | Novel methods for therapeutic vaccination. | |
Durrant et al. | Colorectal Tumor Immunity | |
Primus et al. | Mice transgenic for the CEA gene as a model for cancer immunotherapy and antibody targeting studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020422 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040213 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 31/70 B Ipc: 7A 61K 39/40 B Ipc: 7A 61K 39/00 B Ipc: 7C 07K 16/42 B Ipc: 7A 61K 39/44 B Ipc: 7A 01N 43/04 B Ipc: 7A 61K 39/42 B Ipc: 7A 61K 38/00 A Ipc: 7A 61K 39/395 B Ipc: 7C 07K 7/08 B |
|
17Q | First examination report despatched |
Effective date: 20051019 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080501 |